Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma

被引：0
|
作者：
M Ladetto
S Ferrero
D Drandi
M Festuccia
F Patriarca
N Mordini
S Cena
R Benedetto
G Guarona
F Ferrando
L Brunello
P Ghione
V Boccasavia
R Fanin
P Omedè
L Giaccone
A Palumbo
R Passera
M Boccadoro
B Bruno
机构：
[1] A.O.U. Città della Salute e della Scienza di Torino,Division of Hematology
[2] University of Torino,Department of Molecular Biotechnology and Health Sciences
[3] University of Torino,Division of Hematology
[4] Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo,Division of Hematology
[5] A.O.U,Division of Nuclear Medicine
[6] Udine,undefined
[7] DISM,undefined
[8] University of Udine,undefined
[9] Ospedale ‘S.Croce e Carle’,undefined
[10] Statistical Consultant,undefined
[11] A.O.U. Città della Salute e della Scienza di Torino,undefined
来源：
Leukemia | 2016年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1211 / 1214
页数：3
相关论文
共 50 条
  • [21] Tandem transplant with autografting followed by non-myeloablative allografting for treatment of multiple myeloma: an Italian multi center trial
    Bruno, B
    Patriarca, F
    Maloney, D
    Mordini, N
    Casini, M
    Rambaldi, A
    Carnevale-Schianca, F
    Allione, B
    Soligo, D
    Bavaro, P
    Rotta, M
    Aitoro, G
    Corradini, P
    Todisco, E
    Busca, A
    Fanin, R
    Gallamini, A
    Coser, P
    Levis, A
    Aglietta, M
    Pogliani, E
    Falda, M
    Massaia, M
    Palumbo, A
    Sandmaier, B
    Storb, R
    Boccadoro, M
    BONE MARROW TRANSPLANTATION, 2003, 31 : S148 - S148
  • [22] Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma
    Korthals, Mark
    Sehnke, Nina
    Kronenwett, Ralf
    Schroeder, Thomas
    Strapatsas, Tobias
    Kobbe, Guido
    Haas, Rainer
    Fenk, Roland
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (07) : 1109 - 1115
  • [23] Advances in minimal residual disease monitoring in multiple myeloma
    Wijnands, Charissa
    Noori, Somayya
    van de Donk, Niels W. C. J.
    VanDuijn, Martijn M.
    Jacobs, Joannes F. M.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2023, 60 (07) : 518 - 534
  • [24] Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
    San-Miguel, Jesus
    Avet-Loiseau, Herve
    Paiva, Bruno
    Kumar, Shaji
    Dimopoulos, Meletios A.
    Facon, Thierry
    Mateos, Maria-Victoria
    Touzeau, Cyrille
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Cook, Gordon
    Cavo, Michele
    Quach, Hang
    Ukropec, Jon
    Ramaswami, Priya
    Pei, Huiling
    Qi, Mia
    Sun, Steven
    Wang, Jianping
    Krevvata, Maria
    DeAngelis, Nikki
    Heuck, Christoph
    Van Rampelbergh, Rian
    Kudva, Anupa
    Kobos, Rachel
    Qi, Ming
    Bahlis, Nizar J.
    BLOOD, 2022, 139 (04) : 492 - 501
  • [25] Molecular detection of minimal residual disease in multiple myeloma
    Bai, Yinlei
    Orfao, Alberto
    Sang Chim, Chor
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) : 11 - 26
  • [26] MOLECULAR MONITORING OF BAALC AS A MINIMAL RESIDUAL DISEASE MARKER IN PATIENTS WITH NEWLY DIAGNOSED ACUTE LEUKEMIA
    Najima, Y.
    Ohashi, K.
    Yamashita, T.
    Akiyama, H.
    Sakamaki, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 212 - 212
  • [27] A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
    Silvennoinen, Raija Helena
    Waage, Anders
    Peceliunas, Valdas
    Schjesvold, Fredrik
    Mdphd
    Anttila, Pekka
    Saily, Marjaana
    Putkonen, Mervi
    Carlson, Kristina
    Haukaas, Einar
    Sankelo, Marja
    Partanen, Anu
    Szatkowski, Damian L.
    Hansson, Markus
    Marttila, Anu
    Ahlberg, Lucia
    Axelsson, Per
    Lauri, Birgitta
    Mikkola, Maija Helena
    Karlsson, Conny
    Abelsson, Johanna
    Ahlstrand, Erik
    Sikio, Anu
    Klimkowska, Monika
    Matuzeviciene, Reda
    Fenstad, Mona Hoysaeter
    Ilveskero, Sorella
    Nahi, Hareth
    BLOOD, 2020, 136
  • [28] Autografting followed by non-myeloablative allografting (NST) induces high complete remissions in high risk multiple myeloma.
    Beltrami, G
    Corsetti, MT
    Musto, P
    Carella, AM
    Scalzulli, PR
    Greco, MM
    Lerma, E
    Carella, AM
    BLOOD, 2002, 100 (11) : 622A - 622A
  • [29] Monitoring of minimal residual disease after allografting: A requirement to guide DLI treatment?
    Dazzi, F
    ANNALS OF HEMATOLOGY, 2002, 81 : S29 - S30
  • [30] Salvage non-myeloablative allogeneic transplantation after failure of an autologous transplantation in multiple myeloma
    Qazilbash, MH
    Saliba, R
    Mendoza, F
    Roden, L
    Hosing, C
    Couriel, DE
    Kebriaci, W
    Popat, U
    De Lima, M
    Champlin, RE
    Giralt, SA
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 117 - 117
12345